MARKET

RDY

RDY

Dr Reddys Labs
NYSE

Real-time Quotes | Nasdaq Last Sale

56.48
+1.41
+2.56%
After Hours: 56.48 0 0.00% 16:00 05/24 EDT
OPEN
56.17
PREV CLOSE
55.07
HIGH
56.67
LOW
55.66
VOLUME
111.17K
TURNOVER
0
52 WEEK HIGH
75.50
52 WEEK LOW
47.88
MARKET CAP
9.37B
P/E (TTM)
35.77
1D
5D
1M
3M
1Y
5Y
BRIEF-Dr. Reddy's Laboratories & Senores Pharmaceuticals Announce Launch Of Ketorolac Tromethamine Tablets Usp, 10 Mg In U.S. Market
reuters.com · 10h ago
Dr. Reddy's Laboratories And Senores Pharmaceuticals, Inc. Announce The Launch Of Ketorolac Tromethamine Tablets USP, 10mg In The U.S. Market
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY,
Benzinga · 11h ago
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
Zacks · 4d ago
Dr. Reddy's Laboratories Fiscal Q4 Earnings Decline, Revenue Rises
MT Newswires · 4d ago
Dr. Reddy's GAAP EPS of $0.07, revenue of $717M beats by $54.69M
Dr. Reddy's press release (NYSE:RDY): Q4 GAAP EPS of $0.07. Revenue of $717M (+11.0% Y/Y) beats by $54.69M.
Seekingalpha · 5d ago
Notable earnings before Thursday's open
BJ, CAE, CAN, DESP, EXP, GOGL, GOOS, GRAB, KSS, LSPD, NGG, NM, NNOX, PLCE, RDY, VIPS, WMS, OTCPK:XIACF For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 6d ago
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
HYDERABAD, India & PRINCETON, N.J., April 20, 2022--Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market.
Business Wire · 04/20 16:41
Dr. Reddy’s launches methylprednisolone sodium succinate for injection in US
Dr. Reddy’s Laboratories (NYSE:RDY) launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL, in the U.S. market. The medicine is used to treat several conditions including arthritis,
Seekingalpha · 04/05 12:01
More
No Data
Learn about the latest financial forecast of RDY. Analyze the recent business situations of Dr Reddys Labs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RDY stock price target is 64.47 with a high estimate of 69.00 and a low estimate of 59.00.
High69.00
Average64.47
Low59.00
Current 56.48
EPS
Actual
Estimate
0.210.430.640.86
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 202
Institutional Holdings: 19.75M
% Owned: 11.90%
Shares Outstanding: 165.95M
TypeInstitutionsShares
Increased
50
1.88M
New
19
359.07K
Decreased
42
1.85M
Sold Out
21
268.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Satish Reddy
Co-Chairman/Managing Director/Director
G.V. Prasad
Chief Executive Officer
Erez Israeli
Chief Financial Officer
Parag Agarwal
Corporate Executive
Patrick Aghanian
Corporate Executive
Marc Kikuchi
Corporate Executive
M. Ramana
Chief Human Resource Officer
Archana Bhaskar
Chief Information Officer
Mukesh Rathi
Chief Compliance Officer/Secretary
K. Randhir Singh
General Counsel
Vivek Mittal
Other
Raymond De Vre
Other
Sauri Gudlavalleti
Other
Anil Namboodiripad
Other
Deepak Sapra
Other
Sanjay Sharma
Other
P. Yugandhar
Independent Director
K. Krishnan
Independent Director
Penny Wan
Non-Executive Independent Director
Bruce Carter
Non-Executive Independent Director
Bharat Doshi
Non-Executive Independent Director
Sridar Iyengar
Non-Executive Independent Director
Prasad Menon
Non-Executive Independent Director
Kalpana Morparia
Non-Executive Independent Director
Allan Oberman
Non-Executive Independent Director
Leo Puri
Non-Executive Independent Director
Shikha Sharma
No Data
No Data
About RDY
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

Webull offers kinds of Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.